Prevent Minor Bacterial Skin Infection — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for prevent minor bacterial skin infection. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
4
Active US patents
71/100
Avg vulnerability
—
Annual revenue covered

Originators in Prevent Minor Bacterial Skin Infection

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Fresenius Kabi 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating prevent minor bacterial skin infection. Each bar = one year. Y-axis scaled to peak year (2 patents).

1
26
1
29
2
35

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Lignospan Forte
Lidocaine Hydrochloride
 Fresenius Kabi 4 71 — 2026-07-24

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8759401 Lignospan Forte method of use 85 2026-07-24
8540665 Lignospan Forte method of use 73 2029-10-22
9358338 Lignospan Forte method of use 62 2035-04-27
9370622 Lignospan Forte method of use 62 2035-09-28

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9370622 Lignospan Forte method of use 62 2035-09-28
9358338 Lignospan Forte method of use 62 2035-04-27
8540665 Lignospan Forte method of use 73 2029-10-22
8759401 Lignospan Forte method of use 85 2026-07-24

Related